91360 Med Tech Nets ￥10M in New Round Financing

According to VCBeat, recently, Nanjing-based Nine One Thirty Zero Medical Technology Co., Ltd. ("91360 Med Tech"), a company focusing on the development of "digital pathology + AI", announced the completion of a new funding round of tens of millions, led by Qianyuan Fund. Proceeds from the latest round will mainly be used for the R&D of products, optimization of its production chain, and further exploration of data value, etc. Thus, 91360 Med Tech will accelerate the application of AI and digitalization in the field of pathology.

Founded in 2012, 91360 Med Tech has been committed to grasp the trend of the pathological industry. With "digital pathology + AI" as the core, the company has built a digital platform for scientific and standardized operation of the pathology department to provide users with timely, comprehensive, and professional solutions.

The whole-process informatization solution in pathology covers the daily work of pathology departments with the highlight of "creating paperless work, all-time tracking of sample status, and full coverage of pathological process". The AI-based pathologic solution is jointly developed by China, Japan and the United States to realize the smart pathology department. Relying on its pathologists and partners around the world, the 91360 pathologic consultation platform will provide domestic medical institutions with remote pathological consultation of difficult cases.

When it comes to the future plan, Di Feng, the founder of 91360 Med Tech, said that 91360 will continue to build a complete industry chain through "digital solution + pathology expert service + hardware facilities + reagent and consumables + supply chain transformation" to advance the digitalization in the industry.

Founded in October 2015, Qianyuan Fund is a professional investment company engaged in securities and investment management. It focuses on the pathology industry in recent years and its affiliated fund has injected nearly 2 billion yuan into the IVD field.